Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma

Eiji Oki, Shinji Okano, Hiroshi Saeki, Yuichiro Umemoto, Koji Teraishi, Yu Nakaji, Koji Ando, Yoko Zaitsu, Nami Yamashita, Masahiko Sugiyama, Yuichiro Nakashima, Kippei Ohgaki, Yoshinao Oda, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿記事

9 引用 (Scopus)

抄録

Objectives: Programmed death 1 (PD-1) is an immunoinhibitory receptor and has been identified as a new target for immunotherapy in cancer. Here we report the expression of PD-1 ligand 1 (PD-L1) in surgically resected gastric cancer. Materials and Methods: We examined formalin-fixed tumor samples from 144 gastric cancer patients with a primary diagnosis of gastric carcinoma. Immunohistochemistry was used to detect PD-L1. Human epidermal growth factor receptor 2 (HER2) expression and phosphatase and tensin homolog (PTEN) loss of heterozygosity were investigated in these patients. RNA interference was used to downregulate HER2 expression, and PD-L1 protein expression was assessed by flow cytometry using the gastric cancer cell line MKN45. Results: Overexpression of PD-L1 was significantly correlated with tumor invasion (p = 0.011) and associated with poor survival. The number of PD-L1-positive cases increased according to the HER2 score in clinical samples. siRNA-mediated downregulation of HER2 significantly decreased PD-L1 protein expression in MKN45 cells. Conclusions: PD-L1 expression was associated with poor survival of gastric cancer, and HER2 signaling affects the expression of PD-L1 in gastric cancer. In gastric cancer, PTEN and HER2 are potential candidate biomarkers for developing human antibodies that block PD-L1.

元の言語英語
ページ(範囲)387-394
ページ数8
ジャーナルOncology (Switzerland)
93
発行部数6
DOI
出版物ステータス出版済み - 12 1 2017

Fingerprint

Stomach
Ligands
Carcinoma
Stomach Neoplasms
Proteins
Phosphoric Monoester Hydrolases
Down-Regulation
human ERBB2 protein
Neoplasms
Survival
Loss of Heterozygosity
RNA Interference
Immunotherapy
Formaldehyde
Small Interfering RNA
Flow Cytometry
Biomarkers
Immunohistochemistry
Cell Line
Antibodies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Oki, E., Okano, S., Saeki, H., Umemoto, Y., Teraishi, K., Nakaji, Y., ... Maehara, Y. (2017). Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma. Oncology (Switzerland), 93(6), 387-394. https://doi.org/10.1159/000479231

Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma. / Oki, Eiji; Okano, Shinji; Saeki, Hiroshi; Umemoto, Yuichiro; Teraishi, Koji; Nakaji, Yu; Ando, Koji; Zaitsu, Yoko; Yamashita, Nami; Sugiyama, Masahiko; Nakashima, Yuichiro; Ohgaki, Kippei; Oda, Yoshinao; Maehara, Yoshihiko.

:: Oncology (Switzerland), 巻 93, 番号 6, 01.12.2017, p. 387-394.

研究成果: ジャーナルへの寄稿記事

Oki, E, Okano, S, Saeki, H, Umemoto, Y, Teraishi, K, Nakaji, Y, Ando, K, Zaitsu, Y, Yamashita, N, Sugiyama, M, Nakashima, Y, Ohgaki, K, Oda, Y & Maehara, Y 2017, 'Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma', Oncology (Switzerland), 巻. 93, 番号 6, pp. 387-394. https://doi.org/10.1159/000479231
Oki, Eiji ; Okano, Shinji ; Saeki, Hiroshi ; Umemoto, Yuichiro ; Teraishi, Koji ; Nakaji, Yu ; Ando, Koji ; Zaitsu, Yoko ; Yamashita, Nami ; Sugiyama, Masahiko ; Nakashima, Yuichiro ; Ohgaki, Kippei ; Oda, Yoshinao ; Maehara, Yoshihiko. / Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma. :: Oncology (Switzerland). 2017 ; 巻 93, 番号 6. pp. 387-394.
@article{1000829e8d59436abd6c08bd9a7043ff,
title = "Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma",
abstract = "Objectives: Programmed death 1 (PD-1) is an immunoinhibitory receptor and has been identified as a new target for immunotherapy in cancer. Here we report the expression of PD-1 ligand 1 (PD-L1) in surgically resected gastric cancer. Materials and Methods: We examined formalin-fixed tumor samples from 144 gastric cancer patients with a primary diagnosis of gastric carcinoma. Immunohistochemistry was used to detect PD-L1. Human epidermal growth factor receptor 2 (HER2) expression and phosphatase and tensin homolog (PTEN) loss of heterozygosity were investigated in these patients. RNA interference was used to downregulate HER2 expression, and PD-L1 protein expression was assessed by flow cytometry using the gastric cancer cell line MKN45. Results: Overexpression of PD-L1 was significantly correlated with tumor invasion (p = 0.011) and associated with poor survival. The number of PD-L1-positive cases increased according to the HER2 score in clinical samples. siRNA-mediated downregulation of HER2 significantly decreased PD-L1 protein expression in MKN45 cells. Conclusions: PD-L1 expression was associated with poor survival of gastric cancer, and HER2 signaling affects the expression of PD-L1 in gastric cancer. In gastric cancer, PTEN and HER2 are potential candidate biomarkers for developing human antibodies that block PD-L1.",
author = "Eiji Oki and Shinji Okano and Hiroshi Saeki and Yuichiro Umemoto and Koji Teraishi and Yu Nakaji and Koji Ando and Yoko Zaitsu and Nami Yamashita and Masahiko Sugiyama and Yuichiro Nakashima and Kippei Ohgaki and Yoshinao Oda and Yoshihiko Maehara",
year = "2017",
month = "12",
day = "1",
doi = "10.1159/000479231",
language = "English",
volume = "93",
pages = "387--394",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma

AU - Oki, Eiji

AU - Okano, Shinji

AU - Saeki, Hiroshi

AU - Umemoto, Yuichiro

AU - Teraishi, Koji

AU - Nakaji, Yu

AU - Ando, Koji

AU - Zaitsu, Yoko

AU - Yamashita, Nami

AU - Sugiyama, Masahiko

AU - Nakashima, Yuichiro

AU - Ohgaki, Kippei

AU - Oda, Yoshinao

AU - Maehara, Yoshihiko

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Objectives: Programmed death 1 (PD-1) is an immunoinhibitory receptor and has been identified as a new target for immunotherapy in cancer. Here we report the expression of PD-1 ligand 1 (PD-L1) in surgically resected gastric cancer. Materials and Methods: We examined formalin-fixed tumor samples from 144 gastric cancer patients with a primary diagnosis of gastric carcinoma. Immunohistochemistry was used to detect PD-L1. Human epidermal growth factor receptor 2 (HER2) expression and phosphatase and tensin homolog (PTEN) loss of heterozygosity were investigated in these patients. RNA interference was used to downregulate HER2 expression, and PD-L1 protein expression was assessed by flow cytometry using the gastric cancer cell line MKN45. Results: Overexpression of PD-L1 was significantly correlated with tumor invasion (p = 0.011) and associated with poor survival. The number of PD-L1-positive cases increased according to the HER2 score in clinical samples. siRNA-mediated downregulation of HER2 significantly decreased PD-L1 protein expression in MKN45 cells. Conclusions: PD-L1 expression was associated with poor survival of gastric cancer, and HER2 signaling affects the expression of PD-L1 in gastric cancer. In gastric cancer, PTEN and HER2 are potential candidate biomarkers for developing human antibodies that block PD-L1.

AB - Objectives: Programmed death 1 (PD-1) is an immunoinhibitory receptor and has been identified as a new target for immunotherapy in cancer. Here we report the expression of PD-1 ligand 1 (PD-L1) in surgically resected gastric cancer. Materials and Methods: We examined formalin-fixed tumor samples from 144 gastric cancer patients with a primary diagnosis of gastric carcinoma. Immunohistochemistry was used to detect PD-L1. Human epidermal growth factor receptor 2 (HER2) expression and phosphatase and tensin homolog (PTEN) loss of heterozygosity were investigated in these patients. RNA interference was used to downregulate HER2 expression, and PD-L1 protein expression was assessed by flow cytometry using the gastric cancer cell line MKN45. Results: Overexpression of PD-L1 was significantly correlated with tumor invasion (p = 0.011) and associated with poor survival. The number of PD-L1-positive cases increased according to the HER2 score in clinical samples. siRNA-mediated downregulation of HER2 significantly decreased PD-L1 protein expression in MKN45 cells. Conclusions: PD-L1 expression was associated with poor survival of gastric cancer, and HER2 signaling affects the expression of PD-L1 in gastric cancer. In gastric cancer, PTEN and HER2 are potential candidate biomarkers for developing human antibodies that block PD-L1.

UR - http://www.scopus.com/inward/record.url?scp=85029452141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029452141&partnerID=8YFLogxK

U2 - 10.1159/000479231

DO - 10.1159/000479231

M3 - Article

C2 - 28910818

AN - SCOPUS:85029452141

VL - 93

SP - 387

EP - 394

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 6

ER -